Special Issue "HIV Vaccine"
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 13856
Interests: HIV vaccines; immunogen design and discovery; neutralizing and non-neutralizing antibodies; immune responses; HIV pathogenesis
Since HIV-1 was first identified in the early 1980s, tremendous progress in determining the different aspects of its life cycle and pathogenesis have been made, and this knowledge has led to the development of novel anti-retroviral drugs that have transformed HIV/AIDS from a terminal illness into a chronic disease. Antiretroviral therapy coupled with other prevention modalities have dramatically reduced the rates of new infections and AIDS-related mortality. However, UNAIDS estimated that 36.9 million people worldwide are still living with HIV/AIDS, and ~1.8 million people became newly infected with HIV-1 in 2017. Thus, the development of a safe and effective vaccine remains our best hope for controlling the HIV/AIDS pandemic. Unfortunately, developing a vaccine that can elicit robust protection against HIV infection is a daunting challenge. Thus far, several clinical trials have been conducted, but only one, the RV144 trial, was successful. Although the protection produced by the tested vaccine was modest and short lived, this trial offered the first glimmer of hope that development of an HIV vaccine is possible, although the road to its discovery remains arduous.
This Special Issue of Vaccines on the “HIV vaccine” aims to highlight the unprecedented challenges and the advances that have been made in HIV-1 vaccine field since the RV144 trial. The issue will include research articles, reviews, and short communications on topics including, but not limited to, novel approaches to elicit protective innate, humoral, and cellular responses; the induction of neutralizing and non-neutralizing antibodies and their roles in protection; epitope-based and antibody lineage-based HIV-1 vaccine approaches; and advances in vaccine vectors and adjuvants. The issue will also highlight the unique challenges associated with HIV-1 vaccine development including the high mutability, extreme glycosylation, and poor immunogenicity of HIV-1, the lack of a validated animal model that can fully recapitulate the infection and pathogenesis of HIV in humans, and the lack of definitive correlates of vaccine protection. Thus, this issue will showcase the incredible achievements made in the HIV-1 vaccine field in the last decade.
Dr. Chitra Upadhyay
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- envelope glycosylation
- broadly neutralizing antibodies
- non-neutralizing antibodies
- fc-mediated function
- antibody lineage
- prophylaxis and protection
- humoral and cellular response
- immune correlates
- clinical trials
- animal models